CN1176657C - 含有头孢唑啉和β-内酰胺酶抑制剂的药物组合物 - Google Patents
含有头孢唑啉和β-内酰胺酶抑制剂的药物组合物 Download PDFInfo
- Publication number
- CN1176657C CN1176657C CNB021592942A CN02159294A CN1176657C CN 1176657 C CN1176657 C CN 1176657C CN B021592942 A CNB021592942 A CN B021592942A CN 02159294 A CN02159294 A CN 02159294A CN 1176657 C CN1176657 C CN 1176657C
- Authority
- CN
- China
- Prior art keywords
- cefazolin sodium
- beta
- tazobactam
- sodium
- clavulanic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003781 beta lactamase inhibitor Substances 0.000 title claims abstract description 27
- 229940126813 beta-lactamase inhibitor Drugs 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 title claims description 25
- 239000003814 drug Substances 0.000 title claims description 13
- 229940079593 drug Drugs 0.000 title claims description 3
- 229960001139 cefazolin Drugs 0.000 title abstract description 8
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 title abstract description 8
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims abstract description 43
- 229960003324 clavulanic acid Drugs 0.000 claims abstract description 43
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 claims abstract description 42
- 238000002360 preparation method Methods 0.000 claims abstract description 34
- 229960003865 tazobactam Drugs 0.000 claims abstract description 28
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 230000002195 synergetic effect Effects 0.000 claims abstract description 7
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 claims description 84
- 229960003408 cefazolin sodium Drugs 0.000 claims description 84
- 238000000034 method Methods 0.000 claims description 32
- 238000002347 injection Methods 0.000 claims description 31
- 239000007924 injection Substances 0.000 claims description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 229910052708 sodium Inorganic materials 0.000 claims description 9
- 239000011734 sodium Substances 0.000 claims description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 230000000845 anti-microbial effect Effects 0.000 claims description 4
- -1 granula subtilis Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 18
- 239000012467 final product Substances 0.000 description 24
- 241000894006 Bacteria Species 0.000 description 18
- 238000012360 testing method Methods 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 102000006635 beta-lactamase Human genes 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- NDIURPSCHWTXDC-UHFFFAOYSA-N 2-(4,5-dimethoxy-2-nitrophenyl)acetohydrazide Chemical compound COC1=CC(CC(=O)NN)=C([N+]([O-])=O)C=C1OC NDIURPSCHWTXDC-UHFFFAOYSA-N 0.000 description 7
- 108090000204 Dipeptidase 1 Proteins 0.000 description 7
- 229940038649 clavulanate potassium Drugs 0.000 description 7
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 description 7
- 229960000373 tazobactam sodium Drugs 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000002949 hemolytic effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229960005256 sulbactam Drugs 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002132 β-lactam antibiotic Substances 0.000 description 3
- 229940124586 β-lactam antibiotics Drugs 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000588914 Enterobacter Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 229940020837 cefazolin 500 mg Drugs 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 210000003555 cloaca Anatomy 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940080428 lactose 200 mg Drugs 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 210000003314 quadriceps muscle Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 230000003462 zymogenic effect Effects 0.000 description 2
- LHNIIDJCEODSHA-OQRUQETBSA-N (6r,7r)-3-[(e)-2-(2,4-dinitrophenyl)ethenyl]-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@H]1[C@H]2SCC(=C(N2C1=O)C(=O)O)\C=C\C=1C(=CC(=CC=1)[N+]([O-])=O)[N+]([O-])=O)C(=O)CC1=CC=CS1 LHNIIDJCEODSHA-OQRUQETBSA-N 0.000 description 1
- HOKIDJSKDBPKTQ-UHFFFAOYSA-N 3-(acetyloxymethyl)-7-[(5-amino-5-carboxypentanoyl)amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)C(NC(=O)CCCC(N)C(O)=O)C12 HOKIDJSKDBPKTQ-UHFFFAOYSA-N 0.000 description 1
- 241000588624 Acinetobacter calcoaceticus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 108020004256 Beta-lactamase Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 208000031650 Surgical Wound Infection Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940098164 augmentin Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229940020834 cefazolin 1000 mg Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940041006 first-generation cephalosporins Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229960000614 sulbactam sodium Drugs 0.000 description 1
- RFMIKMMOLPNEDG-QVUDESDKSA-M tazobactam sodium Chemical compound [Na+].C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C([O-])=O)(=O)=O)N1C=CN=N1 RFMIKMMOLPNEDG-QVUDESDKSA-M 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- 229940027257 timentin Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
葡萄球菌 | 25 |
金黄葡萄球菌 | 20 |
肠链球菌 | 4 |
溶血性链球菌 | 10 |
肺炎球菌 | 2 |
绿脓杆菌 | 27 |
大肠杆菌 | 15 |
枸椽酸杆菌 | 4 |
奇异变形杆菌 | 3 |
肺炎杆菌 | 34 |
伤寒杆菌 | 6 |
志贺氏菌 | 4 |
流感杆菌 | 10 |
阴沟肠杆菌 | 3 |
乙酸钙不动杆菌 | 15 |
金葡菌(25) | 表葡菌(20) | 其球他菌G+(16) | 大杆肠菌(28) | 克菌雷属伯(34) | 肠菌杆属(18) | 假菌单属孢(27) | 不菌动属杆(15) | 其杆他菌G(27) | |
克拉维酸 | 512/512 | 512/512 | 512/512 | 512/512 | 512/512 | 512/512 | 512/512 | 512/512 | 512/512 |
他佐巴坦 | 512/512 | 512/512 | 512/512 | 512/512 | 512/512 | 512/512 | 512/512 | 512/512 | 512/512 |
头孢唑啉 | 512/512 | 512/512 | 256/512 | 256/512 | 128/512 | 256/512 | 512/512 | 128/512 | 128/512 |
头孢唑啉-克拉维酸 | |||||||||
1∶1 | 16/64 | 4/64 | 16/64 | 8/32 | 8/8 | 32/64 | 64/64 | 64/64 | 16/64 |
2∶1 | 32/128 | 32/64 | 32/64 | 16/64 | 16/16 | 32/128 | 64/256 | 64/128 | 32/64 |
4∶1 | 128/128 | 64/128 | 64/64 | 32/64 | 32/32 | 64/128 | 64/128 | 64/256 | 32/128 |
8∶1 | 128/256 | 128/128 | 64/128 | 64/128 | 64/64 | 128/256 | 128/256 | 128/256 | 64/256 |
头孢唑啉-他佐巴坦 | |||||||||
1∶1 | 8/32 | 2/32 | 8/16 | 1/4 | 2/4 | 8/32 | 16/32 | 32/64 | 8/8 |
2∶1 | 16/32 | 4/32 | 16/32 | 4/8 | 8/8 | 16/32 | 32/64 | 64/64 | 8/16 |
4∶1 | 32/64 | 16/64 | 32/64 | 16/32 | 16/16 | 32/64 | 32/128 | 64/128 | 16/32 |
8∶1 | 64/128 | 64/128 | 32/128 | 32/64 | 16/64 | 32/128 | 64/256 | 128/256 | 32/128 |
感染菌 药物 ED50/(mgkg-1)MLD(Cfu.mouse-1) |
金黄色葡萄球菌 头孢唑啉 7.7(5.3-10.1)3.1×105 头孢唑啉克拉维酸2∶1 2.7(1.5-4.1)4∶1 3.1(1.8-4.6)头孢唑啉他佐巴坦2∶1 1.9(1.1-3.5)4∶1 2.3(1.4-3.8) |
埃希氏大肠杆菌 头孢唑啉 0.42(0.25-59)6.9×106 头孢唑啉克拉维酸2∶1 0.8(0.53-1.20)4∶1 0.92(0.84-1.27)头孢唑啉他佐巴坦2∶1 0.57(0.32-0.85)4∶1 0.68(0.49-0.96) |
绿脓杆菌 头孢唑啉 40.5(32.3-51.8)5.7×104 头孢唑啉克拉维酸2∶1 11.9(8.8-14.7)4∶1 17.2(13.7-22.1)头孢唑啉他佐巴坦2∶1 8.2(6.7-10.0)4∶1 10.5(7.8-13.9) |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021592942A CN1176657C (zh) | 2002-12-30 | 2002-12-30 | 含有头孢唑啉和β-内酰胺酶抑制剂的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021592942A CN1176657C (zh) | 2002-12-30 | 2002-12-30 | 含有头孢唑啉和β-内酰胺酶抑制剂的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1424039A CN1424039A (zh) | 2003-06-18 |
CN1176657C true CN1176657C (zh) | 2004-11-24 |
Family
ID=4753287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB021592942A Expired - Lifetime CN1176657C (zh) | 2002-12-30 | 2002-12-30 | 含有头孢唑啉和β-内酰胺酶抑制剂的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1176657C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102813658B (zh) * | 2011-06-10 | 2015-04-22 | 深圳华润九新药业有限公司 | 一种五水头孢唑林钠和他唑巴坦钠或其水合物的组合物 |
-
2002
- 2002-12-30 CN CNB021592942A patent/CN1176657C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1424039A (zh) | 2003-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11529361B2 (en) | Halogenated salicylanilides for treating Clostridium infections | |
Ensink et al. | In‐vitro susceptibility to antimicrobial drugs of bacterial isolates from horses in The Netherlands | |
CN1965838A (zh) | 含头孢匹胺和β-内酰胺酶抑制剂的药物组合物 | |
CN114129547B (zh) | 香芹酚在提高耐甲氧西林金黄色葡萄球菌对β-内酰胺类抗生素敏感性方面的应用 | |
JP2961182B2 (ja) | クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物 | |
Cunha et al. | Single daily high-dose tigecycline therapy of a multidrug-resistant (MDR) Klebsiella pneumoniae and Enterobacter aerogenes nosocomial urinary tract infection | |
CN101031321A (zh) | 口服抗菌组合物 | |
CN1176657C (zh) | 含有头孢唑啉和β-内酰胺酶抑制剂的药物组合物 | |
CN115350197B (zh) | 泽泻醇A-24-醋酸酯在提高MRSA对β-内酰胺类抗生素敏感性方面的应用 | |
CN101849947B (zh) | 一种头孢西酮钠和他唑巴坦钠的组合物及其配比 | |
CN1729983A (zh) | 头孢羟氨苄和β-内酰胺酶抑制剂的药物组合物 | |
CN103933543A (zh) | 利用穿心莲和粘杆菌素治疗畜禽大肠杆菌感染疾病的方法 | |
CN103933544A (zh) | 一种含穿心莲和粘杆菌素的畜禽用复方药物 | |
CN1259919C (zh) | 一种杀菌、抑菌药物组合物及其制剂和制备工艺 | |
EP3733176B1 (en) | Composition comprising piperacillin, pharmaceutical preparation thereof and use thereof | |
Sande | Antimicrobial therapy for two serious bacterial infections: enterococcal endocarditis and nosocomial pneumonia | |
CN102462683B (zh) | 一种抗菌素组合物、其制备方法和用途 | |
CN102462686A (zh) | 一种用于防治畜禽大肠杆菌病的药物组合物 | |
CN1657046A (zh) | 一种由头孢哌酮钠和克拉维酸钾组成的注射用粉针剂 | |
CN100341887C (zh) | 门冬氨酸阿奇霉素及其制剂 | |
CN1565457A (zh) | 一种抑制β-内酰胺酶的抗菌组合药物 | |
CN101912402B (zh) | 一种头孢西酮钠和克拉维酸钾的组合物及其配比 | |
CN1305375A (zh) | 抗菌剂 | |
CN1608624A (zh) | 一种供临床使用的注射用头孢泊肟盐 | |
CN102462682B (zh) | 一种抗菌素组合物、其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: YUEKANG PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: YUEKANG MEDICINE CO., LTD., BEIJING |
|
CP03 | Change of name, title or address |
Address after: 100176 No. 6, Hongda Middle Road, Beijing Economic Development Zone, Beijing Patentee after: YOUCARE PHARMACEUTICAL GROUP Co.,Ltd. Address before: 100176, 6, Hongda Middle Road, Yizhuang Development Zone, Beijing, Daxing District Patentee before: Yuekang Medicine Co.,Ltd. Bejiing |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160825 Address after: 100176, Hongda Road, Beijing economic and Technological Development Zone, No. 6 Patentee after: YOUCARE PHARMACEUTICAL GROUP Co.,Ltd. Patentee after: SHANGHAI XINFENG PHARMACEUTICAL Co.,Ltd. Address before: 100176 No. 6, Hongda Middle Road, Beijing Economic Development Zone, Beijing Patentee before: YOUCARE PHARMACEUTICAL GROUP Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 100176, Hongda Road, Beijing economic and Technological Development Zone, No. 6 Co-patentee after: SHANGHAI XINFENG PHARMACEUTICAL Co.,Ltd. Patentee after: Yuekang Pharmaceutical Group Co.,Ltd. Address before: 100176, Hongda Road, Beijing economic and Technological Development Zone, No. 6 Co-patentee before: SHANGHAI XINFENG PHARMACEUTICAL Co.,Ltd. Patentee before: YOUCARE PHARMACEUTICAL GROUP Co.,Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20041124 |